PriceTargets.com logo

SOPHiA GENETICS - SOPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $7.40
  • Forecasted Upside: 126.99%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$3.26 As of 12/20/2024 06:16 PM ET
▲ +0.16 (5.16%)

This chart shows the closing price for SOPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New SOPHiA GENETICS Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SOPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SOPH

Analyst Price Target is $7.40
▲ +126.99% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for SOPHiA GENETICS in the last 3 months. The average price target is $7.40, with a high forecast of $11.00 and a low forecast of $5.00. The average price target represents a 126.99% upside from the last price of $3.26.

This chart shows the closing price for SOPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in SOPHiA GENETICS. This rating has held steady since July 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/18/2024Craig HallumInitiated CoverageBuy$11.00
8/7/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$8.00 ➝ $7.00
8/7/2024Morgan StanleyDowngradeOverweight ➝ Equal Weight$10.00 ➝ $5.00
6/27/2024GuggenheimInitiated CoverageBuy$6.00
3/6/2024BTIG ResearchBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
3/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$8.00
1/12/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$8.00
11/29/2023Royal Bank of CanadaInitiated CoverageOutperform$8.00
3/8/2023Morgan StanleyLower TargetOverweight$12.00 ➝ $11.00
1/3/2023BTIG ResearchInitiated CoverageBuy$6.00
11/23/2022Credit Suisse GroupInitiated CoverageNeutral$2.00
11/9/2022Morgan StanleyLower TargetOverweight$13.00 ➝ $12.00
8/10/2022Morgan StanleyLower TargetOverweight$14.00 ➝ $13.00
3/16/2022Morgan StanleyLower TargetOverweight$18.00 ➝ $17.00
2/15/2022Morgan StanleyLower TargetOverweight$23.00 ➝ $18.00
10/15/2021CowenInitiated CoverageOutperform
8/17/2021CowenInitiated CoverageOutperform
8/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight$23.00
8/17/2021Morgan StanleyInitiated CoverageOverweight$24.00
8/17/2021Credit Suisse GroupInitiated CoverageOutperform$22.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 0 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 3 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

SOPHiA GENETICS logo
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.
Read More

Today's Range

Now: $3.26
Low: $3.16
High: $3.31

50 Day Range

MA: $3.42
Low: $3.10
High: $3.99

52 Week Range

Now: $3.26
Low: $2.70
High: $7.37

Volume

28,920 shs

Average Volume

62,542 shs

Market Capitalization

$213.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of SOPHiA GENETICS?

The following equities research analysts have issued stock ratings on SOPHiA GENETICS in the last year: BTIG Research, Craig Hallum, Guggenheim, Morgan Stanley, and Royal Bank of Canada.
View the latest analyst ratings for SOPH.

What is the current price target for SOPHiA GENETICS?

0 Wall Street analysts have set twelve-month price targets for SOPHiA GENETICS in the last year. Their average twelve-month price target is $7.40, suggesting a possible upside of 127.0%. Craig Hallum has the highest price target set, predicting SOPH will reach $11.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $5.00 for SOPHiA GENETICS in the next year.
View the latest price targets for SOPH.

What is the current consensus analyst rating for SOPHiA GENETICS?

SOPHiA GENETICS currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SOPH.

What other companies compete with SOPHiA GENETICS?

Other companies that are similar to SOPHiA GENETICS include 89bio, Pliant Therapeutics, Relay Therapeutics, Keros Therapeutics and Anavex Life Sciences. Learn More about companies similar to SOPHiA GENETICS.

How do I contact SOPHiA GENETICS's investor relations team?

The company's listed phone number is 41-21-694-1060. The official website for SOPHiA GENETICS is www.sophiagenetics.com. Learn More about contacing SOPHiA GENETICS investor relations.